Lv6
2120 积分 2020-12-07 加入
Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial
18天前
已完结
Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial
18天前
已关闭
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial
18天前
已完结
Long-term survival and cure fraction in patients with advanced hepatocellular carcinoma under immunotherapy in randomized controlled trials and real-world data
29天前
已关闭
Tidal microfluidic chip-based isolation and transcriptomic profiling of plasma extracellular vesicles for clinical monitoring of high-risk patients with hepatocellular carcinoma-associated precursors
29天前
已完结
Current and emerging strategies for the prevention of hepatocellular carcinoma
29天前
已完结
Neoadjuvant, Adjuvant, or Both? Optimizing Perioperative Systemic Therapy in Lung Cancer
1个月前
已关闭
Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial
1个月前
已完结
Establishing five-year overall survival as a new standard for trials in advanced HCC
1个月前
已完结
Cancer profiles in China and comparisons with the USA: a comprehensive analysis in the incidence, mortality, survival, staging, and attribution to risk factors
1个月前
已完结
皖公网安备34019202002308
